View:
Download DOC
Download PDF
Download XLS
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2022

Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  

EXHIBIT INDEX

 

Exhibit Title
     
99.1 Press Release dated August 4, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Cellectis S.A.    
  (Registrant)
   
  
Date: August 4, 2022     /s/ André Choulika    
  André Choulika
  Chief Executive Officer
  
EdgarFiling

EXHIBIT 99.1

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

 

NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided business update and announced its results for the six-month period ending June 30, 2022.

“This is a very exciting time at Cellectis: earlier this week, we were proud to announce the FDA clearance of our Investigational New Drug application for UCART20x22, our product candidate being developed for patients with relapsed and refractory Non-Hodgkin Lymphoma,” said André Choulika, Ph.D., Chief Executive Officer at Cellectis. “UCART20x22 is a very promising product candidate. Dual targeting of CD20 and CD22, both validated targets in B-cell malignancies, represents a potential therapeutic alternative to CD19-directed therapies.

In 2018, Cellectis made the decision to internalize manufacturing for its therapeutic product candidates, with the goal of providing the company with manufacturing independence. UCART20x22 is the first example of achieving this milestone, as our first product candidate with fully integrated in-house development. It showcases our transformation into an end-to-end cell and gene therapy company, from discovery & product development, transfer, and GMP manufacturing and clinical development. We are very excited to start the clinical trial for patients with relapsed or refractory Non-Hodgkin Lymphoma in the second half of this year.

We continue to make progress enrolling patients in our three Cellectis-sponsored Phase 1 dose escalation trials and take notable steps forward with our partnerships programs. These updates illustrate our potential and ability to advance the field of allogeneic CAR T cell therapy.”

Pipeline highlights

Cellectis continues to make progress, enrolling patients throughout its sponsored Phase 1 dose escalation trials:

BALLI-01 (evaluating UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

AMELI-01 (evaluating UCART123) in relapsed or refractory acute myeloid leukemia (r/r AML)

MELANI-01 (evaluating UCARTCS1) in relapsed or refractory multiple myeloma (r/r MM)

NatHaLi-01 (evaluating UCART20x22) in relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL)

UCART Preclinical Data & Programs

Novel universal CAR T-cell

Licensed Allogeneic CAR-T Cell Development Programs

Allogene Therapeutics, Inc.’s CAR T programs utilize Cellectis technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Les Laboratoires Servier (“Servier”) and Allogene Therapeutics, Inc. (“Allogene”) based on an exclusive license granted by Cellectis to Servier2. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. Allogene’s anti-BCMA and anti-CD70 programs are licensed exclusively from Cellectis to Allogene and Allogene holds global development and commercial rights to these programs.

Anti-CD19 program

Anti-BCMA program

Anti-CD70 program

Gene Editing Partnerships

Iovance Biotherapeutics, Inc. (“Iovance”)

Cytovia Therapeutics, Inc. (“Cytovia”)

Corporate Updates

Financial Results

The interim condensed consolidated financial statements of Cellectis, which consolidate the results of Calyxt, Inc. of which Cellectis owned approximately 51.3% of outstanding shares of common stock (as of June 30, 2022), have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”).

We present certain financial metrics broken out between our two reportable segments – Therapeutics and Plants – in the appendices of this Q2 2022 financial results press release.

Cash: As of June 30, 2022, Cellectis, including Calyxt, had $135 million in consolidated cash, cash equivalents, and restricted cash of which $123 million are attributable to Cellectis on a stand-alone basis. This compares to $191 million in consolidated cash, cash equivalents and restricted cash as of December 31, 2021, of which $177 million was attributable to Cellectis on a stand-alone basis. This net decrease of $56 million primarily reflects (i) $56 million of net cash flows used in operating, investing and lease financing activities of Cellectis, (ii) $13 million of net cash flows used in operating, capital expenditures and lease financing activities of Calyxt, and (iii) a $4 million defavorable FOREX impact which was partially offset by (i) $10 million of net proceeds from capital raise at Calyxt and, (ii) $5 million of cash received related to research tax credit prefinancing. Based on the current operating plan, Cellectis excluding Calyxt anticipates that the cash, cash equivalents, and restricted cash of $123 million as of June 30, 2022 will fund its operations into early 2024.

Revenues and Other Income: Consolidated revenues and other income were $7 million for the six months ended June 30, 2022 compared to $43 million for the six months ended June 30, 2021. 99% of consolidated revenues and other income was attributable to Cellectis in the first six months of 2022. This decrease between the six months ended June 30, 2022 and 2021 was mainly attributable to (i) a decrease of revenue pursuant to the recognition of a $15.0 million convertible note obtained as consideration for a “right-to-use” license granted to Cytovia and a $5.1 million Allogene milestone during the six-month period ended June 30, 2021, while revenue related to collaboration agreements for the six months of 2022 consists of the recognition of two milestones related to Cellectis’ agreement with Cytovia for $1.5 million and the recognition of $1.0 million related to a change of control of a licensee pursuant to the terms of the license agreement with Cellectis and amendment to the license agreement (extension of the option term) (ii) a decrease in other revenues of $5 million relating to a change in Calyxt’s business model for its PlantSpring technology and BioFactory, in which no significant revenue was yet recognized.

Cost of Revenues: Consolidated cost of revenues were $0,7 million for the six months ended June 30, 2022 compared to $20 million for the six months ended June 30, 2021. This decrease is driven by the change in Calyxt’s business model for its PlantSpring and BioFactory.

R&D Expenses: Consolidated R&D expenses were $59 million for the six months ended June 30, 2022 compared to $62 million for the six months ended June 30, 2021. 89% of consolidated R&D expenses was attributable to Cellectis in the first six months of 2022. The $3 million decrease between the first six months of 2022 and 2021 was primarily attributable to (i) a decrease of purchases, external expenses and other by $4.5 million (from $36 million in 2021 to $31 million in 2022) due to lower consumables, subcontracting costs and depreciation and amortization for the therapeutic segment, (ii) a $0.9 million decrease in social charges on stock option, and (iii) a $0.9 million decrease in non-cash stock-based compensation expense partially offset by an increase of $3 million in wages and salaries mainly driven by the increased R&D headcount in the therapeutic segment.

SG&A Expenses: Consolidated SG&A expenses were $17.7 million for the six months ended June 30, 2022 compared to $18.2 million for the six months ended June 30, 2021. 62% of consolidated SG&A expenses was attributable to Cellectis in the first six months of 2022. The $0.5 million decrease primarily reflects (i) a $3 million decrease in wages and salaries, (ii) a $0.3 million decrease in social charges on stock option grants and (iii) a $0.5 million decrease in purchases, external expenses and other (from $9.2 million in 2021 to $8.7 million in 2022) partially offset by (i) a $3 million increase in non-cash stock-based compensation expense mainly explained by the favorable impact in 2021 of the recapture of non-cash stock-based compensation from the forfeiture of certain of Calyxt’s former CEO’s unvested stock options, restricted stock units, and performance stock units following his departure.

Net Income (loss) Attributable to Shareholders of Cellectis: The consolidated net loss attributable to shareholders of Cellectis was $51 million (or $1.12 per share) for the six months ended June 30, 2022, of which $47 million was attributed to Cellectis, compared to $52 million (or $1.17 per share) for the six months ended June 30, 2021, of which $43 million was attributed to Cellectis. This $1 million decrease in net loss between first six months 2022 and 2021 was primarily driven by (i) an increase in net financial gain of $14.7, (ii) a decrease of $19 million of cost of revenue and, (iii) a $3.8 million decrease of research and development expenses partially offset by a decrease in revenues and other income of $36 million.

Adjusted Net Income (Loss) Attributable to Shareholders of Cellectis: The consolidated adjusted net loss attributable to shareholders of Cellectis was $46 million (or $1.00 per share) for the six months ended June 30, 2022, of which $43 million is attributed to Cellectis, compared to a net loss of 48 million (or $1.08 per share) for the six months ended June 30, 2021, of which $38 million was attributed to Cellectis. Please see "Note Regarding Use of Non-GAAP Financial Measures" for reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis to adjusted net income (loss) attributable to shareholders of Cellectis.

We currently foresee focusing our cash spending at Cellectis for the Full Year of 2022 in the following areas:

CELLECTIS S.A. 
(unaudited) 
STATEMENT OF CONSOLIDATED FINANCIAL POSITION 
($ in thousands, except per share data)

  As of
  December 31, 2021 June 30, 2022
     
     
ASSETS     
Non-current assets     
Intangible assets 1 854  1 584 
Property, plant, and equipment 78 846  73 953 
Right-of-use assets 69 423  61 086 
Non-current financial assets 6 524  9 093 
Total non-current assets  156 647  145 716 
     
Current assets     
Trade receivables 20 361  2 602 
Subsidies receivables 9 268  11 244 
Other current assets 9 665  7 694 
Cash and cash equivalent and Current financial assets 186 135  153 626 
Total current assets  225 429  175 167 
TOTAL ASSETS  382 076  320 883 
     
LIABILITIES     
Shareholders’ equity     
Share capital 2 945  2 946 
Premiums related to the share capital 934 696  567 284 
Currency translation adjustment (18 021) (29 626)
Retained earnings (584 129) (320 812)
Net income (loss) (114 197) (50 858)
Total shareholders’ equity - Group Share 221 293  168 933 
Non-controlling interests 15 181  11 588 
Total shareholders’ equity 236 474  180 522 
     
Non-current liabilities     
Non-current financial liabilities 20 030  15 636 
Non-current lease debts 71 526  66 591 
Non-current provisions 4 073  2 852 
Non-current liabilities 626  - 
Total non-current liabilities  96 254  85 079 
     
Current liabilities     
Current financial liabilities 2 354  11 310 
Current lease debts 8 329  8 091 
Trade payables 23 762  24 159 
Deferred revenues and deferred income 301  400 
Current provisions 871  440 
Other current liabilities 13 731  10 884 
Total current liabilities  49 348  55 282 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  382 076  320 883 

Cellectis S.A.
UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS
For the three-month period ended June 30, 2022
$ in thousands, except per share amounts

  For the three-month period ended June 30,
     2021   2022 
       
Revenues and other income      
Revenues 11 176  1 348 
Other income 3 439  1 416 
Total revenues and other income 14 615  2 765 
Operating expenses    
Cost of revenue (11 754) (329)
Research and development expenses (31 147) (29 048)
Selling, general and administrative expenses (9 343) (8 415)
Other operating income (expenses) 150  952 
Total operating expenses (52 096) (36 842)
     
Operating income (loss) (37 481) (34 077)
     
Financial gain (loss) (4 129) 14 623 
     
Net income (loss) (41 610) (19 454)
Attributable to shareholders of Cellectis (39 919) (18 947)
Attributable to non-controlling interests (1 691) (506)
     
Basic net income (loss) attributable to shareholders of Cellectis per share ($/share) (0,88) (0,42)
     
Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share) (0,88) (0,42)

Cellectis S.A.
UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS
For the six-month period ended June 30, 2022
$ in thousands, except per share amounts

  For the six-month period ended June 30,
  2021  2022 
    
Revenues and other income    
Revenues 36 777  3 045 
Other income 5 804  3 551 
Total revenues and other income 42 581  6 596 
Operating expenses    
Cost of revenue (19 899) (714)
Research and development expenses (62 338) (58 527)
Selling, general and administrative expenses (18 219) (17 695)
Other operating income (expenses) 488  1 016 
Total operating expenses (99 968) (75 920)
     
Operating income (loss) (57 387) (69 324)
     
Financial gain (loss) 431  15 113 
     
Net income (loss) (56 956) (54 211)
Attributable to shareholders of Cellectis (51 787) (50 858)
Attributable to non-controlling interests (5 169) (3 352)
Basic net income (loss) attributable to shareholders of Cellectis per share ($/share) (1,17) (1,12)
     
Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share) (1,17) (1,12)

CELLECTIS S.A.
DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE SEGMENTS – Second Quarter
(unaudited) - ($ in thousands)

  For the three-month period ended June 30, 2021 For the three-month period ended June 30, 2022
$ in thousands PlantsTherapeuticsTotal reportable segments PlantsTherapeuticsTotal reportable segments
         
External revenues 11 728 (552)11 176  42 1 307 1 348 
External other income 1 528 1 911 3 439  - 1 416 1 416 
External revenues and other income13 256 1 359 14 615  42 2 723 2 765 
Cost of revenue (11 337)(418)(11 754) 0 (329)(329)
Research and development expenses (2 810)(28 336)(31 147) (3 419)(25 630)(29 048)
Selling, general and administrative expenses (3 410)(5 933)(9 343) (3 585)(4 830)(8 415)
Other operating income and expenses 31 118 150  198 753 951 
Total operating expenses (17 526)(34 569)(52 096) (6 806)(30 036)(36 842)
Operating income (loss) before tax (4 270)(33 210)(37 481) (6 764)(27 313)(34 077)
Financial gain (loss) (294)(3 836)(4 129) 6 322 8 301 14 623 
Net income (loss)  (4 564)(37 046)(41 610) (442)(19 012)(19 454)
Non controlling interests 1 691 - 1 691  506 - 506 
Net income (loss) attributable to shareholders of Cellectis (2 873)(37 046)(39 919) 64 (19 012)(18 946)
R&D non-cash stock-based expense attributable to shareholder of Cellectis 271 2 398 2 669  226 1 454 1 681 
SG&A non-cash stock-based expense attributable to shareholder of Cellectis 373 593 966  447 557 1 003 
Adjustment of share-based compensation attributable to shareholders of Cellectis 644 2 991 3 635  673 2 011 2 684 
Adjusted net income (loss) attributable to shareholders of Cellectis (2 229)(34 055)(36 285) 737 (17 001)(16 264)
Depreciation and amortization (614)(2 768)(3 382) (608)(4 500)(5 108)
Additions to tangible and intangible assets 39 4 688 4 727  308 870 1 178 

CELLECTIS S.A.
DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE SEGMENTS – First six-months
(unaudited) - ($ in thousands)

  For the six-month period ended June 30, 2021 For the six-month period ended June 30, 2022
$ in thousands PlantsTherapeuticsTotal reportable segments PlantsTherapeuticsTotal reportable segments
         
External revenues 16 716 20 061 36 777  73 2 972 3 045 
External other income 1 528 4 276 5 804  - 3 551 3 551 
External revenues and other income 18 244 24 337 42 581  73 6 523 6 596 
Cost of revenue (18 706)(1 194)(19 899) (0)(714)(714)
Research and development expenses (5 836)(56 503)(62 338) (6 297)(52 231)(58 527)
Selling, general and administrative expenses (7 528)(10 691)(18 219) (6 801)(10 893)(17 695)
Other operating income and expenses 7 482 489  242 774 1 016 
Total operating expenses (32 063)(67 905)(99 968) (12 856)(63 064)(75 920)
Operating income (loss) before tax (13 818)(43 569)(57 387) (12 783)(56 541)(69 324)
Net financial gain (loss) (584)1 015 431  5 900 9 213 15 113 
Net income (loss)  (14 402)(42 554)(56 956) (6 883)(47 328)(54 211)
Non-controlling interests 5 169 - 5 169  3 352 - 3 352 
Net income (loss) attributable to shareholders of Cellectis (9 233)(42 554)(51 787) (3 531)(47 328)(50 858)
R&D non-cash stock-based expense attributable to shareholder of Cellectis 532 3 703 4 235  216 3 134 3 349 
SG&A non-cash stock-based expense attributable to shareholder of Cellectis (918)916 (2) 789 1 193 1 982 
Adjustment of share-based compensation attributable to shareholders of Cellectis (385)4 619 4 233  1 005 4 327 5 331 
Adjusted net income (loss) attributable to shareholders of Cellectis (9 619)(37 935)(47 554) (2 526)(43 001)(45 527)
Depreciation and amortization (1 218)(5 954)(7 173) (1 316)(9 434)(10 749)
Additions to tangible and intangible assets 308 11 020 11 327  671 1 452 2 123 

Note Regarding Use of Non-IFRS Financial Measures

Cellectis S.A. presents adjusted net income (loss) attributable to shareholders of Cellectis in this press release. Adjusted net income (loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to net income (loss) attributable to shareholders of Cellectis, which is the most directly comparable financial measure calculated in accordance with IFRS. Because adjusted net income (loss) attributable to shareholders of Cellectis excludes Non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis’ financial performance. Moreover, our management views the Company’s operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of Non-cash stock-based expenses from Net income (loss) attributable to shareholders of Cellectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of adjusted net income (loss) attributable to shareholders of Cellectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of Non-cash stock- based compensation expense differently; and (b) other companies may report adjusted net income (loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider adjusted net income (loss) attributable to shareholders of Cellectis alongside our IFRS financial results, including Net income (loss) attributable to shareholders of Cellectis.

RECONCILIATION OF IFRS TO NON-IFRS NET INCOME – Second Quarter
(unaudited)
($ in thousands, except per share data)

  For the three-month period ended June 30,
  2021  2022 
     
Net income (loss) attributable to shareholders of Cellectis  (39 919) (18 947)
Adjustment:
        Non-cash stock-based compensation expense attributable to shareholders of Cellectis		 3 635  2 684 
Adjusted net income (loss) attributable to shareholders of Cellectis (36 284) (16 264)
     
Basic Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (0,80) (0,36)
     
Weighted average number of outstanding shares, basic (units) (1) 45 461 310  45 507 921 
     
Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1) (0,80) (0,36)
     
Weighted average number of outstanding shares, diluted (units) (1) 45 461 310  45 507 921 
  1. When we have adjusted net loss, in accordance with IFRS, we use the Weighted average number of outstanding shares, basic to compute the Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share). When we have adjusted net income, in accordance with IFRS, we use the Weighted average number of outstanding shares, diluted to compute the Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share)

RECONCILIATION OF IFRS TO NON-IFRS NET INCOME – First six-months 
(unaudited)
($ in thousands, except per share data)

  For the six-month period ended June 30,
  2021  2022 
    
Net income (loss) attributable to shareholders of Cellectis  (51 787) (50 858)
Adjustment:
        Non-cash stock-based compensation expense attributable to shareholders of Cellectis		 4 233  5 331 
Adjusted net income (loss) attributable to shareholders of Cellectis (47 554) (45 527)
     
Basic Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1,08) (1,00)
     
Weighted average number of outstanding shares, basic (units) (1) 44 163 914  45 497 127 
     
Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1) (1,08) (1,00)
     
Weighted average number of outstanding shares, diluted (units) (1) 44 163 914  45 497 127 

(1) When we have adjusted net loss, in accordance with IFRS, we use the Weighted average number of outstanding shares, basic to compute the Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share). When we have adjusted net income, in accordance with IFRS, we use the Weighted average number of outstanding shares, diluted to compute the Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share)

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:  

Media contacts:  
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300  

Investor Relation contact:  
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com  
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Forward-looking Statements

This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,” “could,” “would” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners. Forward-looking statements include statements about advancement, timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentation of data and submission of regulatory filings, the operational capabilities at our manufacturing facilities, the potential of our preclinical programs, and the sufficiency of cash to fund operations. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

1 Cash position includes cash, cash equivalents and current financial assets and restricted cash. Restricted cash was $5 million as of June 30, 2022.
2 Servier is a global independent pharmaceutical group.

 

Attachment